阿托伐他汀对冠心病并慢性心力衰竭患者血清肌钙蛋白I水平及预后的影响

目的 研究阿托伐他汀治疗对冠心病(CHD)并慢性心力衰竭(CHF)患者血清肌钙蛋白I(cTnI)水平及预后的影响.方法 将92例CHD并CHF住院患者随机分成两组,他汀组及非他汀组各46例,治疗前两组性别、年龄、并存疾病如高血压及糖尿病、NYHA心功能分级、左室射血分数(LVEF)、左室舒张末期内径(LVEDD)差异无...

Effects of atorvastatin on the levels of serum cardiac troponin I and the prognosis in patients with coronary heart disease and chronic heart failure

Objective To study the effects of atorvastatin treatment on the levels of serum cardiac troponin I(cTnI) and the prognosis in patients with coronary heart diease (CHD) and chronic heart failure (CHF). Methods 92 consecutive patients hospitaled for CHD and CHF were divided randomly into two groups: the statin group and the no-statin group. There were no significant diferences between the two groups in gender, age, comorbidities such as hypertension and diabetes mellitus, NYHA cardiac functional grading, left ventricular ejection fraction (LVEF) and left ventricular end-diastolic dimension (LVEDD). Patients of the both groups were treated with conventional medication of anti-heart failure strategies, whereas patients in the statin group were received additional atorvastatin 10mg daily. Both groups had been followed up for about one year. The changes of cTnI levels were determined before and after 1-month treatment. The risk of the major adverse cardiovascular events (MACE), including cardiovascular mortality, nonfatal myocardial infarction and stroke, and the rates of rehospitalization for worsening heart failure (HF) were evaluated during 1-year follow-up. Results The levels of cTnI were decreased more significantly in the statin group after one month of treatment(P<0.05). There were overall 25 episodes of MACE during follow-up, 11 (26.2%) and 14 (32.6%) in the statin and the no-statin group, respectively. The readmission rates for worsening HF were 23.8% and 44.2% in the statin and the no-statin group, respectively (P<0.05). Conclusion Atorvastatin could reduce the levels of serum cTnI in patients with CHD and CHF. Regardless of no beneficial effect on the prognosis, it can significantly reduce the rehospitalization rates for worsening HF.